Metabolic Manipulation in Chronic Heart Failure

University Hospital Birmingham NHS Foundation Trust

Status and phase

Completed

Phase 2

Conditions

Chronic Heart Failure

Treatments

Drug: Placebo

Drug: Perhexiline

Study type

Interventional

Funder types

Other

Identifiers

NCT00841139

R&D Birminham: RRK 2785 (Other Identifier)

MHRA: 21761/0003/001 (Other Identifier)

2004-004965-14 (EudraCT Number)

MREC: 06/Q2707/7 (Other Identifier)

Details and patient eligibility

About

Conventional measures used for the treatment of chronic heart failure act predominantly by reducing the work performed by the heart. In a recent study, the investigators showed that one drug (perhexiline) substantially improved symptoms and cardiac function in heart failure. The investigators wish to confirm these findings and test whether or not this drug acts by altering the heart's energy source thus augmenting the energetic status and work efficiency of the heart.

Full description

Perhexiline maleate is an antianginal agent which increases the efficiency of energy production by shifting substrate utilisation from free fatty acids towards glucose. We showed that perhexiline therapy was highly effective in improving exercise capacity, symptoms and cardiac function in patients with systolic heart failure of both ischaemic and non ischaemic aetiology. Perhexiline acts by inhibiting both carnitine palmitoyl transferase-1 (CPT-1) and CPT-2, which are key enzymes in mitochondrial free fatty acid uptake. This leads to increased myocardial glucose substrate utilization. Further we wish to ascertain whether or not this drug improves cardiac energetics and efficiency by altering substrate utilization. In this proposal we will assess the cardiac function (by cardiac Magnetic Resonance Imaging MRI), cardiac energetic status (by cardiac Magnetic Resonance Spectroscopy MRS), cardiac efficiency (via pressure-volume loops) and substrate utilization (via left and right heart catheterization), following one month of perhexiline therapy or placebo in patients with symptomatic idiopathic dilated cardiomyopathy on optimal conventional heart failure medications. An interim analysis is planned after 20 patients.

Enrollment

50 patients

Sex

All

Ages

16 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Optimally-medicated idiopathic dilated cardiomyopathy
Symptomatic ( NYHA IIb-III)
Impaired left ventricular systolic function (EF < 40%)

Exclusion criteria

Abnormal liver function tests (defined as above twice the upper limit of normal (ULN))
Concomitant use of Amiodarone , Quinidine , Haloperidol or Selective serotonin (5HT) uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6 enzyme.
Pre-existing evidence of peripheral neuropathy.
Women of childbearing potential.
Patients with implantable cardiac devices (or any other contraindication to MRI).
Obesity ( BMI > 32)
Obstructive sleep apnea syndrome
Patients with known hypersensitivity to perhexiline
Patients with impaired renal function (Creatinine > 250 µmol/L)
Valvular heart disease defined as more than moderate valvular stenosis or regurgitation.
Atrial Fibrillation